Novo Nordisk shares jump as Eli Lilly obesity pill disappoints

Published 07/08/2025, 13:02
© Reuters

Investing.com -- Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly’s data on its oral obesity drug orforglipron underwhelmed investors, prompting concerns over both efficacy and tolerability.

Wolfe Research described the 11.5% placebo-adjusted weight loss achieved by orforglipron at 72 weeks as “modestly below investor expectations of 13–15%.” 

Analysts said the study clears a key hurdle but noted that both “weight loss and tolerability came in light.”

The highest dose of orforglipron saw treatment discontinuation rates of 24.4%, while even the lower strength showed dropout rates in the mid-teens. 

“We’d flag the 10.3% and 24.4% treatment discontinuation rates... We look to results at EASD, Sept. 17th, to further gauge prescriber sentiment,” Wolfe said, maintaining an Outperform rating on LLY.

Mizuho (NYSE:MFG) analysts echoed concerns about tolerability, calling the outcome “clearly not the ideal outcome here despite [a] good quarter.” 

They pointed to a “near 25% patient drop-out rate on the highest dose” and suggested that the unusually high 29% placebo discontinuation rate “almost does not compute.”

Despite the disappointment, Mizuho believes orforglipron still has long-term potential: “11.2% weight-loss for a pill we think is solid given ease of use... maybe more of a consumer product than a drug.”

However, in the near term, the results appeared to benefit Novo Nordisk (NYSE:NVO). “NVO rallying... as investors believe gap between the two has now narrowed to some extent,” Mizuho noted.

Lilly shares are down more than 7% premarket, despite a strong quarter that included $3.38 billion in Zepbound sales and raised full-year guidance.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.